Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Jinhai International Group Holdings Limited ( (HK:2225) ) has issued an announcement.
Jinhai Medical Technology Limited has announced an updated composition of its board of directors effective 3 February 2026, naming Mr. Chen Guobao as chairman, Mr. Li Bin as co-chairman and Mr. Wang Zhenfei as chief executive officer, alongside other executive, non-executive and independent non-executive directors. The board has also confirmed the membership and chairmanship of its audit, remuneration and nomination committees, with independent directors taking leading roles, signalling an emphasis on strengthened corporate governance and regulatory compliance that may reassure investors and other stakeholders about oversight of the company’s future strategic and operational decisions.
The most recent analyst rating on (HK:2225) stock is a Buy with a HK$2.50 price target. To see the full list of analyst forecasts on Jinhai International Group Holdings Limited stock, see the HK:2225 Stock Forecast page.
More about Jinhai International Group Holdings Limited
Jinhai Medical Technology Limited, listed in Hong Kong under stock code 2225, operates in the medical technology sector. The company is incorporated in the Cayman Islands with limited liability and is governed by a board comprising executive, non-executive and independent non-executive directors, reflecting a typical Hong Kong–listed corporate governance structure for a healthcare-related issuer.
Average Trading Volume: 8,783,473
Technical Sentiment Signal: Buy
Current Market Cap: HK$11.06B
Learn more about 2225 stock on TipRanks’ Stock Analysis page.